| Literature DB >> 33808729 |
Sebastià Mas-Alòs1,2, Antoni Planas-Anzano1,2, Xavier Peirau-Terés1,2, Jordi Real-Gatius3,4, Gisela Galindo-Ortego5.
Abstract
Exercise is related to many individual health outcomes but impact evaluations of exercise programmes are seldom conducted. The purpose of the study is to evaluate the feasibility of an exercise prescription intervention in primary health-care settings (CAMINEM Programme) located in two socially disadvantaged neighbourhoods. The CAMINEM was a pragmatic-driven intervention with opportunistic recruitment. It followed the 5As framework for health promotion and also the exercise training principles. Feasibility was evaluated using the RE-AIM framework (Reach, Effectiveness, Adoption, Implementation, and Maintenance). Patients with non-communicable chronic diseases participated in a 12-month home-based moderate-intensity exercise program, counselled by exercise physiologists. Participants were grouped according to their physical activity behaviour at baseline and 6-month adherence. CAMINEM reached 1.49% (n = 229) of the eligible population (N = 15374) and included a final sample of 178. Health outcomes for adhered participants followed positive patterns. Non-adhered participants visited their practitioner more compared to adhered participants. Thirty-three practitioners (40%) referred patients. Nurses referred four times more than physicians (81% and 19% respectively). The delivery of exercise prescriptions proved to be easy to complete and record by participants as well as easy to monitor and adjust by the exercise physiologists. One out of four participants adhered during the 12-month intervention. This intervention has been feasible in primary care in Catalonia, Spain, to safely prescribe home-based exercise for several conditions.Entities:
Keywords: HEPA; RE-AIM; adherence; community-based participatory research; exercise prescription; health outcomes; implementation science; physical activity; public health; sedentary behavior
Mesh:
Year: 2021 PMID: 33808729 PMCID: PMC8003347 DOI: 10.3390/ijerph18063192
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) Dimensions and their evaluative questions. Based on Glasgow [32] and Estabrooks & Gyurcsik [33].
| RE-AIM Dimension | Evaluative Questions |
|---|---|
| Reach | What percentage of potentially eligible participants will take part and how representative are they? |
| Efficacy or Effectiveness | What impact did the intervention have on all participants who began the program, on process intermediate and primary outcomes, and on both positive and negative (unintended) outcomes including quality of life? |
| Adoption | What percentage of settings and intervention agents will participate and how representative are they? |
| Implementation | To what extent are the various intervention components delivered as intended, especially when conducted by regular staff in applied settings?To what extent did the participants receive and enacts the intervention components? |
| Maintenance | To what extent are different intervention components continued or institutionalized? |
Figure 1Flowchart of the participants included in the CAMINEM intervention. * Patients may have more than one condition. The CAMINEM Programme addressed patients from two primary health-care settings in socially disadvantaged neighbourhoods. All practitioners (physicians and community nurses) were invited to participate. Patients to be included had to be visited by their practitioner during a regular visit, accepted their oral invitation, being referred to the exercise physiologist and finally sign the informed consent. Retention refers to not drop out while adherence shows fulfillment of the exercise prescription.
Participants grouping and reasons for prescription.
| GENDER | PRACTITIONER | SETTING | AGE GROUP | BASAL PA LEVEL a | TOTAL | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Male | Female | Physician | Nurse | A | B | 18–44 | 45–64 | 65+ | Insuffic. | Sufficient | ||||||||||||||
| (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | |||||||||||||
| Reasons for prescriptions b | ||||||||||||||||||||||||
| Overweight | ||||||||||||||||||||||||
| 23 | (36.5) |
| (58.3) |
| (56.7) |
| (49.9) |
| (48.1) | 53 | (52.5) |
| (84.0) | 41 | (44.6) | 28 | (45.9) |
| (59.3) | 36 | (41.9) |
| (50.6) | |
| Hypertension | ||||||||||||||||||||||||
|
| (49.2) | 49 | (42.6) | 9 | (3.0) | 71 | (48.0) | 26 | (33.8) |
| (53.5) | 3 | (12.0) |
| (46.7) |
| (55.7) | 39 | (42.9) |
| (46.5) | 80 | (44.9) | |
| Dyslipidemia | ||||||||||||||||||||||||
| 27 | (42.9) | 37 | (32.2) | 10 | (33.3) | 54 | (36.5) | 22 | (28.6) | 42 | (41.6) | 8 | (32.0) | 35 | (38.0) | 21 | (34.4) | 33 | (36.3) | 31 | (36.0) | 64 | (36.0) | |
| Diabetes Mellitus | ||||||||||||||||||||||||
| 29 | (46.0) | 28 | (24.3) | 3 | (10.0) | 54 | (36.5) | 17 | (22.1) | 40 | (39.6) | 2 | (8.0) | 33 | (35.9) | 22 | (36.1) | 30 | (33.0) | 27 | (31.4) | 57 | (32.0) | |
| Musculoskeletal | ||||||||||||||||||||||||
| 5 | (7.9) | 34 | (29.6) | 10 | (33.3) | 29 | (19.6) | 14 | (18.2) | 25 | (24.8) | 3 | (12.0) | 19 | (20.7) | 17 | (27.9) | 22 | (24.2) | 17 | (19.8) | 39 | (21.9) | |
| Cardiovascular | ||||||||||||||||||||||||
| 17 | (27.0) | 13 | (11.3) | 5 | (16.7) | 25 | (16.9) | 9 | (11.7) | 21 | (20.8) | 2 | (8.0) | 9 | (9.8) | 19 | (31.1) | 16 | (17.6) | 14 | (16.3) | 30 | (16.9) | |
| Respiratory | ||||||||||||||||||||||||
| 15 | (23.8) | 9 | (7.8) | 5 | (16.7) | 19 | (12.8) | 6 | (7.8) | 18 | (17.8) | 1 | (4.0) | 17 | (18.5) | 6 | (9.8) | 11 | (12.1) | 13 | (15.1) | 24 | (13.5) | |
| Mental illness | ||||||||||||||||||||||||
| 2 | (3.2) | 17 | (14.8) | 5 | (16.7) | 14 | (9.5) | 7 | (9.1) | 12 | (11.9) | 1 | (4.0) | 12 | (13.0) | 6 | (9.8) | 11 | (12.1) | 8 | (9.3) | 19 | (10.7) | |
| Other | ||||||||||||||||||||||||
| 5 | (7.9) | 8 | (7.0) | 2 | (6.7) | 11 | (7.4) | 4 | (5.2) | 9 | (8.9) | 1 | (4.0) | 10 | (10.9) | 2 | (3.3) | 8 | (8.8) | 5 | (5.8) | 13 | (7.3) | |
| Number of health conditions | ||||||||||||||||||||||||
| 1 | 16 | (25.4) |
| (32.2) | 9 | (30.0) |
| (29.7) |
| (45.4) | 18 | (17.8) |
| (44.0) |
| (29.3) | 15 | (24.6) | 24 | (26.3) |
| (32.5) |
| (29.8) |
| 2 | 17 | (27.0) | 34 | (29.6) |
| (36.7) | 40 | (27.0) | 24 | (31.2) | 27 | (26.7) |
| (44.0) | 25 | (27.2) |
| (28.7) | 25 | (27.5) | 26 | (30.2) | 51 | (28.7) |
| 3 |
| (28.6) | 28 | (24.3) | 7 | (23.3) | 39 | (26.4) | 13 | (16.9) |
| (32.7) | 3 | (12.0) | 26 | (28.3) | 46 | (25.8) |
| (28.6) | 20 | (23.3) | 46 | (25.8) |
| 4+ | 12 | (19.0) | 16 | (13.9) | 3 | (10.0) | 25 | (16.9) | 5 | (6.5) | 23 | (22.8) | 0 | (0.0) | 14 | (15.2) | 28 | (15.7) | 16 | (17.6) | 12 | (14.0) | 28 | (15.7) |
Note. PA = physical activity; Insuffic. = Insufficient. Bold: the most common condition. a One missing. b The total sums exceed 100%.
Homogeneity for continuous variables at baseline among groups.
| GROUP a | AD-IN | AD-AC | NA-AC | NA-IN | |||||
|---|---|---|---|---|---|---|---|---|---|
| M | SD | M | SD | M | SD | M | SD | ||
| Age * | 56.0 | 9.2 | 64.5 | 6.5 | 59.1 | 13.1 | 55.8 | 12.6 | 0.029 |
| Clinical parameters | |||||||||
| BMI (kg/m2) * | 32.5 | 4.2 | 30.2 | 4.3 | 30.9 | 4.3 | 33.2 | 5.2 | 0.021 |
| Waist circumference (cm) | 111.4 | 15.3 | 102.3 | 8.0 | 105.7 | 11.4 | 106.0 | 9.8 | 0.487 |
| Systolic blood pressure (mmHg) | 131.1 | 11.2 | 140.3 | 15.3 | 134.3 | 17.0 | 134.2 | 15.7 | 0.385 |
| Diastolic blood pressure (mmHg) | 79.2 | 8.6 | 77.1 | 7.4 | 77.6 | 11.0 | 79.8 | 10.8 | 0.575 |
| Resting heart rate (beats/min) | 74.0 | 14.1 | 75.2 | 15.8 | 73.0 | 12.5 | 77.0 | 11.5 | 0.552 |
| Total blood cholesterol (mg/dl) | 201.9 | 26.8 | 203.8 | 40.5 | 202.7 | 41.5 | 207.5 | 38.9 | 0.923 |
| LDL blood cholesterol (mg/dl) | 125.5 | 23.1 | 121.5 | 34.4 | 120.2 | 35.8 | 122.2 | 32.6 | 0.974 |
| Triglyceride (mg/dl) | 144.2 | 69.8 | 155.4 | 88.5 | 155.5 | 94.3 | 153.9 | 70.6 | 0.979 |
| HDL blood cholesterol (mg/dl) | 60.4 | 19.7 | 51.3 | 13.2 | 52.4 | 14.2 | 53.5 | 13.0 | 0.423 |
| Plasma glucose (mg/dl) | 115.2 | 33.5 | 114.5 | 25.5 | 116.9 | 42.8 | 118.9 | 38.9 | 0.970 |
| Glycated haemoglobin (%) b | 7.5 | 1.5 | 7.1 | 0.9 | 7.7 | 1.4 | 7.4 | 1.2 | 0.693 |
| SF-12v2 questionnaire outcomes | |||||||||
| Physical functioning | 44.7 | 8.0 | 54.5 | 4.5 | 45.6 | 7.5 | 45.1 | 9.0 | 0.184 |
| Role physical | 46.1 | 5.3 | 57.4 | 4.7 | 46.0 | 10.4 | 44.2 | 12.8 | 0.161 |
| Bodily pain | 33.4 | 5.9 | 25.3 | 4.6 | 33.7 | 11.6 | 36.4 | 12.9 | 0.272 |
| General health | 40.4 | 5.5 | 48.2 | 9.9 | 40.9 | 6.9 | 40.1 | 8.1 | 0.237 |
| Vitality | 46.0 | 11.3 | 54.2 | 21.0 | 52.9 | 11.6 | 51.3 | 13.8 | 0.547 |
| Social functioning | 41.2 | 9.8 | 51.8 | 10.6 | 46.8 | 12.4 | 44.6 | 12.9 | 0.448 |
| Mental health | 45.5 | 10.7 | 53.9 | 8.4 | 45.4 | 11.8 | 42.5 | 12.4 | 0.251 |
| Role emotional | 50.3 | 13.5 | 47.2 | 10.6 | 49.2 | 11.8 | 50.1 | 12.7 | 0.954 |
| PCS: Summary scale Physical | 39.3 | 5.5 | 45.1 | 2.2 | 39.5 | 6.1 | 39.7 | 6.2 | 0.353 |
| MCS: Summary scale Mental | 48.4 | 14.0 | 53.5 | 9.3 | 51.2 | 13.3 | 49.4 | 15.3 | 0.871 |
| Health-care attendance | |||||||||
| In the year prior to inclusion (visits per month) | 1.1 | 0.6 | 1.5 | 0.9 | 1.6 | 1.2 | 1.5 | 1.2 | 0.574 |
Note. AD-IN = adhered and previously inactive, AD-AC = adhered and previously active, NA-AC = non adhered and previously active, NA-IN = non adhered and previously inactive, BMI = body mass index. * p < 0.05. a 1 missing. b Sample size for participants diagnosed with diabetes mellitus: Total (n = 57), AD-IN (n = 6), AD-AC (n = 9), NA-AC (n = 18), NA-IN (n = 24).
Homogeneity at baseline (M1) between groups by adherence.
| GROUPS | AD-Group | NA-Group | |||
| M | SD | M | SD | ||
| Age | 60.8 | 8.8 | 57.4 | 12.9 | 0.126 |
| Clinical parameters | |||||
| BMI (kg/m2) | 31.2 | 4.3 | 32.2 | 4.9 | 0.466 |
| GROUPS | AD-Group | NA-Group | |||
| (%) | (%) | ||||
| Diagnosed dyslipidaemia | 19 | (29.7) | 45 | (70.3) | 0.022 *,a |
| Diagnosed overweight | 12 | (13.3) | 78 | (86.7) | 0.046 *,b |
Note. AD-Group = adhered, NA-Group = non-adhered, BMI = body mass index, kg = kilogram, m = metre. a Continuity correction = 5.270. b Continuity correction = 3.998. * p < 0.05.
Intention-to-treat multivariate analyses of variance
| Measure | M1 | MOT3 | Signification effects | Evolution | |||||
|---|---|---|---|---|---|---|---|---|---|
| Group | AD ( | NA ( | AD ( | NA ( | Group | Time | AD | NA | |
| HR a | M | 72.9 | 73.6 | 72.7 | 76.2 | 0.21% | −3.50% | ||
| SD | 15.8 | 12.1 | 15.7 | 13.4 | |||||
|
| 14 | 32 | 14 | 32 | Mdif = 2.1 | Mdif = 1.3 | Mdif = 0.1 | Mdif = 2.7 | |
| CHO a | M | 201.2 | 222.3 | 193.4 | 199.0 | 4.06% | 11.71% | ||
| SD | 25.4 | 43.3 | 36.4 | 41.8 | |||||
|
| 13 | 23 | 13 | 23 | Mdif = 13.3 | Mdif = 15.6 95% CI [4.3, 26.9] | Mdif = 7.8 | Mdif = 23.3 | |
| LDL a | M | 125.8 | 127.7 | 127.7 | 115.1 | −1.48% | 10.95% | ||
| SD | 22.2 | 35.0 | 40.4 | 38.4 | |||||
|
| 9 | 14 | 9 | 14 | Mdif = 5.4 | Mdif = 5.4 | Mdif = 1.9 | Mdif = 12.6 | |
| BMI b | M | 30.5 | 33.4 | 29.9 | 32.8 | M1 | MOT3 | 1.99% | 1.91% |
| SD | 4.1 | 4.6 | 4.0 | 4.4 | |||||
|
| 18 | 44 | 18 | 44 | |||||
| WC b | M | 102.6 | 108.7 | 100.6 | 106.75 | M1 | MOT3 | 1.99% | 1.87% |
| SD | 9.09 | 12.3 | 7.2 | 11.3 | |||||
|
| 7 | 8 | 7 | 8 | |||||
| SBP b | M | 137.5 | 135.3 | 138.6 | 130.8 | M1 | MOT3 | −0.76% | 3.50% |
| SD | 15.6 | 15.9 | 16.9 | 14.6 | |||||
|
| 17 | 51 | 17 | 51 | |||||
| DBP b | M | 76.8 | 80.4 | 76.2 | 79.4 | M1 | MOT3 | 0.76% | 1.31% |
| SD | 6.9 | 11.1 | 9.1 | 10.3 | |||||
|
| 17 | 51 | 17 | 51 | |||||
| TG b | M | 144.9 | 171.2 | 112.5 | 145.9 | M1 | MOT3 | 28.77% | 17.37% |
| SD | 70.9 | 90.4 | 43.4 | 87.8 | |||||
|
| 13 | 21 | 13 | 21 | |||||
| HDL b | M | 51.9 | 51.2 | 52.0 | 50.0 | M1 | MOT3 | −0.21% | 2.42% |
| SD | 13.0 | 12.1 | 8.5 | 11.1 | |||||
|
| 9 | 14 | 9 | 14 | |||||
| GLY b | M | 114.4 | 119.1 | 107.2 | 113.0 | M1 | MOT3 | 6.67% | 5.43% |
| SD | 28.9 | 41.7 | 23.5 | 25.3 | |||||
|
| 14 | 21 | 14 | 21 | |||||
| HbA1c
b,c | M | 7.4 | 7.4 | 7.2 | 7.2 | M1 | MOT3 | 2.58% | 1.77% |
| SD | 1.4 | 0.9 | 1.0 | 1.1 | |||||
|
| 7 | 7 | 7 | 7 | |||||
Note. M1 = basal, MOT3 = over time post-intervention, AD = adhered to the intervention, NA = non adhered to the intervention, HR = heart rate, min = minute, Mdif = mean difference, CHO = total cholesterol, mg = milligram, dl = decilitre, CI = confidence interval, BMI = body mass index, kg = kilogram, m = metre, WC = waist circumference, cm = centimetre, SBP = systolic blood pressure, mmHg = millimetres of mercury, DBP = diastolic blood pressure, TG = triglyceride, GLY = fasting glucose. a 2 × 2 multivariate analysis. Age-adjusted comparison. b Mann-Whitney U (pre- and post-intervention) and Wilcoxon’s Z (pre- and post-intervention within group). c Percentage varies due to decimals. * p < 0.05 ** p < 0.01.
Figure 2Health-care provider visits per month by intervention groups. Note. Blue lines = mean. AD-IN = adhered and previously inactive, AD-AC = adhered and previously active, NA-AC = non adhered and previously active, NA-IN = non adhered and previously inactive * stands for “Outliers”.
Distribution of CAMINEM adherence by intervention groups.
| ATTENDANCE | RETENTION | COMPLIANCE | |||||
|---|---|---|---|---|---|---|---|
| Irregular | Regular | <180 d | ≥ 180 d | ExRx not completed | ExRx completed | TOTAL a | |
| GROUP | |||||||
| AD-IN | 0 (0) | 15 (100) | 0 (0) | 15 (100) | 0 (0) | 15 (100) | 15 (100) |
| AD-AC | 0 (0) | 20 (100) | 0 (0) | 20 (100) | 0 (0) | 20 (100) | 20 (100) |
| NA-AC | 27 (40.9) | 39 (59.1) | 61 (92.4) | 5 (7.6) | 34 (51.5) | 32 (48.5) | 66 (100) |
| NA-IN | 39 (51.3) | 37 (48.7) | 69 (90.8) | 7 (9.2) | 48 (63.2) | 28 (36.8) | 76 (100) |
Note. ExRx = exercise prescription, AD-IN = adhered and previously inactive, AD-AC = adhered and previously active, NA-AC, not adhered and previously active, NA-IN = not adhered and previously inactive. a 1 missing.